Author(s)

Elvis Han

Corresponding Author

Elvis Han

Abstract

Clustered regularly interspaced palindromic repeats (CRISPR) is a gene-editing technology that has revolutionized the biotechnology industry. With a guide RNA and an endonuclease protein termed CRISPR associated (Cas) protein, the CRISPR-Cas technology is the most programmable and flexible editing technology in comparison to previous alternatives like zinc finger proteins (ZFN) and TALENs. Specifically, CRISPR has made strides in the battle against cancer, HIV, and single-point mutation diseases. However, due to the technology’s recency and relative lack of research, any given treatment is projected to be extremely expensive. This paper explores not only the recent research on treatable diseases but also the affordability and ethics of gene-editing with CRISPR as a whole.

Keywords

Crispr-cas9, Hiv, Cancer